J 2017

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

PROCHAZKA, V.; T. PAPAJIK; Andrea JANÍKOVÁ; D. BELADA; T. KOZAK et. al.

Základní údaje

Originální název

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database

Autoři

PROCHAZKA, V.; T. PAPAJIK; Andrea JANÍKOVÁ; D. BELADA; T. KOZAK; David ŠÁLEK; A. SYKOROVA; H. MOCIKOVA; V. CAMPR; J. DLOUHA; K. LANGOVA; T. FURST a M. TRNENY

Vydání

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2017, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.644

Organizační jednotka

Lékařská fakulta

UT WoS

000393891300013

Klíčová slova anglicky

Autologous transplantation; chemotherapy; follicular lymphoma; prognosis

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 12. 4. 2018 18:53, Soňa Böhmová

Anotace

V originále

Optimal frontline treatment in younger high tumor-burden risk follicular lymphoma patients remains a challenge given the reduced efficacy of standard immunochemotherapy (R-CHOP) in widespread disease and unclear role of intensive induction. The retrospective non-randomized pair-matched (1: 3) analysis compared 48 intermediate/ high Follicular Lymphoma International Prognostic Index (FLIPI) patients receiving intensive rituximab sequential chemotherapy (R-SQ) with 144 random controls (R-CHOP) matched for age, FLIPI score, and maintenance delivery. Complete response rates were 91.7% and 74.1%, respectively (p = .038). After a median followup of 8.8 (R-SQ) and 6.5 years (R-CHOP), 5-year time to treatment failure, progression-free survival, and overall survival were 80.9%, 83.2%, and 100% and 57.5%, 60.3%, and 92.1% (p = .0044; p = .0047; p = .22), respectively. Intensive treatment was accompanied by higher acute hematologic toxicity and infections, comparable non-hematologic toxicity, and incidence of secondary malignancies. Intensive induction demonstrates superior long-term disease control compared to R-CHOP, with higher acute hematologic toxicity, but without acute treatment-related mortality. Further studies are needed to define ultra-high-risk FL patients benefiting most from treatment intensity.